Edition:
United States

AbbVie Inc (ABBV.K)

ABBV.K on New York Consolidated

62.09USD
24 Feb 2017
Change (% chg)

$0.15 (+0.24%)
Prev Close
$61.94
Open
$61.92
Day's High
$62.23
Day's Low
$61.49
Volume
6,536,399
Avg. Vol
7,796,470
52-wk High
$68.12
52-wk Low
$54.01

Latest Key Developments (Source: Significant Developments)

Abbvie sets quarterly cash dividend of $0.64 per share
Thursday, 16 Feb 2017 12:41pm EST 

AbbVie Inc : Maintains quarterly dividend .Sets quarterly cash dividend of $0.64 per share.  Full Article

Neurocrine Biosciences reports Q4 loss per share $0.51
Tuesday, 14 Feb 2017 04:24pm EST 

Neurocrine Biosciences Inc : Neurocrine Biosciences reports year-end 2016 results and provides investor update for 2017 . Q4 loss per share $0.51 . Q4 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S . Neurocrine Biosciences Inc- Revenues from milestones under abbvie agreement for 2017 are expected to be $30 million .Neurocrine Biosciences-2017 ongoing operating expenses should approximate $230 million to $240 million, exclusive of $30 million up-front fee for in-licensing opicapone.  Full Article

Abbvie Inc reports Q4 GAAP earnings per share $0.85
Friday, 27 Jan 2017 07:48am EST 

Abbvie Inc : Abbvie reports full-year and fourth-quarter 2016 financial results . Q4 GAAP earnings per share $0.85 . Q4 revenue $6.796 billion versus I/B/E/S view $6.91 billion . Q4 earnings per share view $1.20 -- Thomson Reuters I/B/E/S . Sees FY 2017 adjusted earnings per share $5.44 to $5.54 . Sees FY 2017 GAAP earnings per share $4.55 to $4.65 . Q4 adjusted earnings per share $1.20 . Abbvie Inc qtrly total Humira sales $4,292 million versus $3,717 million . FY2017 earnings per share view $5.47 -- Thomson Reuters I/B/E/S . Abbvie Inc - 2017 adjusted diluted EPS guidance excludes $0.89 per share of intangible asset amortization expense and other specified items .Abbvie qtrly worldwide adjusted net revenues of $6.784 billion increased 6.9 percent, excluding 0.2 percent unfavorable impact from foreign exchange rate fluctuations.  Full Article

Abbvie initiates phase 2 clinical trial programs for ABBV-8e12
Wednesday, 25 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie initiates phase 2 clinical trial programs for ABBV-8e12, an investigational anti-tau antibody, in early alzheimer's disease and progressive supranuclear palsy.  Full Article

AbbVie, Genomics Medicine and WuXi NextCODE announce Population Genomics alliance
Monday, 9 Jan 2017 08:05am EST 

AbbVie Inc :Abbvie - Co, Genomics Medicine Ireland, WuXi NextCODE announce Population Genomics alliance; financial terms were not disclosed.  Full Article

Abbvie announces four new collaborations and investments with healthcare companies
Monday, 9 Jan 2017 08:00am EST 

Abbvie Inc :Abbvie Inc - announced four new collaborations and investments with healthcare companies.  Full Article

AbbVie, Lurie Cancer Center to collaborate on multi-year cancer research agreement
Monday, 5 Dec 2016 08:50am EST 

AbbVie Inc :AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement.  Full Article

Halozyme provides update on Abbvie collaboration
Monday, 21 Nov 2016 08:30am EST 

Halozyme Therapeutics Inc : Halozyme Therapeutics Inc - abbvie has discontinued a development program using halozyme enhanze platform technology . Halozyme - co, abbvie will continue to work to identify additional targets for co-development under 2015 global collaboration,licensing agreement . Halozyme Therapeutics - abbvie has discontinued development program following completion of a phase 1 study in which target results were not achieved . Halozyme Therapeutics-abbvie discontinued development program using halozyme enhanze platform technology, tnf-alpha target after completion of phase 1 study .Halozyme provides update on abbvie collaboration.  Full Article

Abbvie's Humira® (adalimumab) receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa
Monday, 14 Nov 2016 03:00am EST 

Abbvie Inc : Abbvie's Humira receives CHMP positive opinion to treat adolescents with Hidradenitis Suppurativa, a chronic inflammatory skin disease .Says "if approved, Humira will become first and only biologic treatment option for patients 12 years of age and older".  Full Article

CHMP recommends EU approval of Venclyxto in hard-to-treat CLL-Roche
Friday, 14 Oct 2016 07:16am EDT 

Roche Holding AG :Says : roche announces CHMP recommendation for eu approval of venclyxto for people with hard-to-treat chronic lymphocytic leukaemia.  Full Article

More From Around the Web

Fitch Affirms Astrazeneca at 'A'; Stable Outlook

(The following statement was released by the rating agency) LONDON, February 22 (Fitch) Fitch Rating has affirmed UK-based pharmaceutical company AstraZeneca PLC's (AZ) Long-Term Issuer Default Rating (IDR) and senior unsecured rating at 'A'. The Outlook is Stable. The rating remains underpinned by AZ's leading position in the global pharmaceutical sector, supported by a business risk profile characterised by scale, diversification, and focus on innovation. The group is accelerating the dev